The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

For the meantime, it’s still open, and this weekend is hosting an IWD-themed party promising the “biggest bangers from the ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Five years after Covid, the biotech investment ...

The Nashville singer-songwriter puts her guitar into drop-D tunings and explores new avenues on her sixth solo release ...

Long Islanders can enjoy bangers and mash and shepherd's pie all year-round at a range of traditional Irish pubs and ...

Ariana Grande bewitches the crowd on the red carpet at the 2025 Oscars held at the Dolby Theatre in Hollywood on March 2.

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a positive outlook on MDGL stock.